53874-72-9

Usage

General Description

2-Amino-3,5-dichlorobenzaldehyde is a compound with the molecular formula C7H5Cl2NO. It is a benzaldehyde derivative with two chlorine atoms and an amino group attached to the benzene ring. It is commonly used as an intermediate in the synthesis of pharmaceuticals and organic compounds. The compound has been studied for its potential applications in pharmaceutical research, particularly in the development of new drugs and therapies. Its chemical properties and reactivity make it valuable in the production of various chemical products.

Upstream product

• 59178-12-0 3,5-dichloro-2-nitrobenzaldehyde 
• 10203-08-4 3,5-dichlorobenzaldehyde 
• 37585-29-8 (2-amino-3,5-dichloro-phenyl)-methanol 

Downstream Products

• 1254343-20-8 (S)-5,7-dichloro-2-phenyl-1,2,3,4-tetrahydroacridine 
• 15396-39-1 2-bromo-3,5-dichloro-benzoic acid 
• 873983-89-2 2-bromo-3,5-dichlorobenzaldehyde 

Relevant academic research and scientific papers

Chiral Phosphoric-Acid-Catalyzed Cascade Prins Cyclization

Asymmetric Prins cyclization of in situ generated quinone methides and o-aminobenzaldehyde has been developed with chiral phosphoric acid as an efficient catalyst. This unconventional method provides a facile access to diverse functionalized trans-fused pyrano-/furo-tetrahydroquinoline derivatives in excellent yield and with excellent diastereo- and enantioselectivities (up to 99% yield and 99% ee). Mechanistic studies suggested that the three adjacent tertiary stereocenters were constructed through the sequential formation of C-O, C-C, and C-N bonds.

GLYCINE B ANTAGONISTS

The invention relates to quinoline derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are glycine B antagonists and are therefore useful for the control and prevention of various disorders, including neurological disorders.

HCV INHIBITORS AND METHODS OF USING THEM

The present invention comprises tetrazoloquinoline-compounds that are inhibitors of HCV. Compositions comprising the compounds in combination with a pharmaceutically acceptable carrier are also disclosed, as are methods of using the compounds and composit